Relmada Therapeutics (RLMD) Operating Expenses (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Operating Expenses data on file, last reported at $19.5 million in Q1 2026.

• Quarterly Operating Expenses rose 6.82% year-over-year to $19.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.3 million (down 23.73% YoY) and the FY2025 annual result came in at $59.1 million, down 29.55% from the prior year.
• Operating Expenses declined to $19.5 million in Q1 2026 per RLMD's latest filing, from $20.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $45.5 million in Q2 2022 and bottomed at $10.2 million in Q2 2025.
• The 5-year median for Operating Expenses is $23.0 million (2024), against an average of $25.1 million.
• The widest annual swing landed in 2022, when Operating Expenses jumped 71.99%; it then slumped 55.12% in 2025.
• Tracing RLMD's Operating Expenses over 5 years: stood at $38.7 million in 2022, then slumped by 30.68% to $26.8 million in 2023, then retreated by 28.9% to $19.1 million in 2024, then grew by 6.59% to $20.3 million in 2025, then fell by 4.29% to $19.5 million in 2026.
• Per Business Quant, the three latest RLMD Operating Expenses figures stand at $19.5 million (Q1 2026), $20.3 million (Q4 2025), and $10.3 million (Q3 2025).

Peer Comparison